Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Higashihara,Yoshie; Kato,Junko; Nagahara,Akihito; Izumi,Kentaro; Konishi,Masae; Kodani,Tomohiro; Serizawa,Nobuko; Osada,Taro; Watanabe,Sumio

doi:10.3892/ijo.2013.2242

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Authors:
- Yoshie Higashihara
- Junko Kato
- Akihito Nagahara
- Kentaro Izumi
- Masae Konishi
- Tomohiro Kodani
- Nobuko Serizawa
- Taro Osada
- Sumio Watanabe
View Affiliations

Affiliations: Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
Published online on: December 31, 2013 https://doi.org/10.3892/ijo.2013.2242
Pages: 662-668
Copyright: © Higashihara et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy‑resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A*2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated in a phase I clinical trial of patients with advanced gastric cancer who were refractory to chemotherapy. We determined the HLA genotype of the subjects after enrollment, results of which were held by the evaluation committee and kept from both patients and investigators until completion of the study. The primary end‑point was safety of the peptide vaccination. The secondary end‑points were immunological responses and clinical outcome, which were compared between the HLA-A*2402-positive and HLA-A*2402-negative groups. The peptides were subcutaneously administered on day 1, 8, 15 and 22 within a 28-day treatment cycle. A total of 14 patients was enrolled in this study; 12 of the 14 patients received 4 or more vaccinations (at least 1 course). No patient had a severe treatment-related adverse event. Findings from evaluation of clinical responses after a single course showed that 4 cases had stable disease and 8 cases had progressive disease. The median overall survival time (MST) for the 12 patients was 3.9 months. The MSTs in the HLA-A*2402‑positive and HLA-A*2402‑negative groups were, 4.2 and 3.6 months (p=0.9164), respectively. The results of this study showed that vaccination with URLC10 and VEGFR1 peptides was a safe treatment for advanced gastric cancer. This trial was registered with University Hospital Medical Information Network (UMIN, no. 000002409).

View Figures

View References

1.	Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, et al: Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 10:1266–1279. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordic F, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized control trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
3.	Cheever MA and Higano CS: PROVENGE (Sipuleusel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell esophageal cancer. Cancer Sci. 100:1502–1509. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, et al: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 101:433–439. 2010. View Article : Google Scholar
6.	Kato J, Nagahara A, Kotani T, Higashihara Y, Matsumura Y, Osada T, Yoshizawa T, et al: Phase I clinical trial of peptide vaccination with KIF20 and VEGFR1 epitope peptides in patients with advanced pancreatic cancer. Pancreatic Dis Ther. 2:1022012. View Article : Google Scholar
7.	Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, et al: Heteroclitic serological response in esophageal and prostate cancer patient after NY-ESO-1 protein vaccination. Int J Cancer. 130:584–592. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, Hasegawa S, et al: Identification of immunoglobulin super-family 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinoma. Cancer Sci. 96:498–506. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Komori H, Nakahara T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 12:2689–2697. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, et al: Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancer. Clin Cancer Res. 14:6487–6495. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Kataguri T, Fukukawa Y, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 10:8630–8640. 2004. View Article : Google Scholar
12.	Ishizaki H, Tsynoda T, Wada S, Yamauchi M, Shibuya M and Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 12:5841–5849. 2006. View Article : Google Scholar
13.	Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, et al: Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 99:1448–1454. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, et al: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 10:1412012. View Article : Google Scholar
15.	Suda T, Tsunoda T, Daigo Y, Nakamura Y and Tahara H: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancer as novel targets for immunotherapy. Cancer Sci. 98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Fujiwara Y, Kishi K, Yano M, Mototsugu M, Ishikawa O, Okada K, Masuzawa T, et al: Peptide vaccination for gastric cancer. J Gastrointest Res. 20:120–127. 2012.
17.	Van der Brunggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde, Kunth A, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
18.	Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 23:8950–8958. 2005.
19.	Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki H and Okumo K: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother. 58:1843–1852. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y and Furukawa Y: Identification of TOMMO34, which shows elevated expression in the majority of human colon cancer, as a novel drug target. Int J Oncol. 29:381–386. 2006.PubMed/NCBI
21.	Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, et al: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 41:1297–1304. 2012.
22.	Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, et al: Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 94:802–808. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 7:3950–3962. 2001.PubMed/NCBI
24.	Koizumi W, Nakahara H, Hara T, Takigane A, Akiya T, Takagi M, Miyashita K, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI